睡眠1号胶囊联合舒肝解郁胶囊治疗肝郁脾虚型失眠的疗效观察

Observation on the Therapeutic Effect of Sleeping No.1 Capsule Combined with Shugan Jieyu Capsule on Insomnia of Liver Depression and Spleen Deficiency Type

目的:探讨睡眠1号胶囊联合舒肝解郁胶囊治疗肝郁脾虚型失眠的临床效果。方法:选取2020年5月至2022年6月福建省南平市人民医院收治的失眠患者88例作为研究对象,按照随机数字表法分为对照组和观察组,每组44例。对照组口服舒肝解郁胶囊治疗,观察组加用睡眠1号胶囊治疗,持续用药8周。比较2组临床疗效、睡眠质量、心理状态、生命质量及不良反应。结果:观察组总有效率较对照组高,治疗后睡眠潜伏期、觉醒时间为(40.33±4.35)min、(65.42±5.21)min,短于对照组的(45.46±4.77)min、(70.96±6.15)min,睡眠总时间为(7.22±1.24)h,长于对照组的(6.13±1.18)h,匹兹堡睡眠质量指数(PSQI)评分为(5.58±1.04)分,低于对照组的(7.19±1.13)分,差异有统计学意义(P<0.05);观察组治疗后焦虑自评量表(SAS)评分、抑郁自评量表(SDS)评分为(37.54±4.08)分、(38.87±4.25)分,低于对照组的(43.41±4.22)分、(45.27±4.43)分,差异有统计学意义(P<0.05);观察组治疗后生理、心理、社会及环境领域评分为(90.63±4.37)分、(93.74±3.82)分、(89.85±5.78)分、(94.58±2.14)分,高于对照组的(84.15±6.85)分、(86.63±6.89)分、(82.55±6.43)分、(87.51±6.85)分,差异有统计学意义(P<0.05);2组不良反应比较,差异无统计学意义(P>0.05)。结论:睡眠1号胶囊联合舒肝解郁胶囊可提高肝郁脾虚型失眠治疗效果,加快睡眠质量恢复,减轻心理障碍,改善患者生命质量,安全可靠。

Objective:To investigate the clinical effect of Sleep No.1 Capsule combined with Shugan Jieyu Capsule in the treatment of insomnia of liver depression and spleen deficiency and its influence on sleep quality.Methods:A total of 88 patients with insomnia admitted to the People′s Hospital of Nanping City,Fujian Province from May 2020 to June 2022 were selected as the research subjects.They were randomly divided into a control group and an observation group using a random number table method,with 44 patients in each group.The control group was orally treated with Shugan Jieyu Capsules,while the observation group was treated with Sleep No.1 Capsules for 8 weeks.Compare the clinical efficacy,sleep quality,psychological state,quality of life,and adverse reactions between two groups.Results:The total effective rate of the observation group was higher than that of the control group.After treatment,the sleep latency and awakening time were(40.33±4.35)minutes and(65.42±5.21)minutes,which were shorter than the control group′s(45.46±4.77)minutes and(70.96±6.15)minutes.The total sleep time was(7.22±1.24)hours,longer than the control group′s(6.13±1.18)hours,and the Pittsburgh Sleep Quality Index(PSQI)score was(5.58±1.04)points,lower than the control group′s(7.19±1.13)points,The difference was statistically significant(P<0.05);After treatment,the SAS and SDS scores of the observation group were(37.54±4.08)and(38.87±4.25),which were lower than those of the control group(43.41±4.22)and(45.27±4.43),and the difference was statistically significant(P<0.05).After treatment,the physiological,psychological,social,and environmental scores in the observation group were(90.63±4.37),(93.74±3.82),(89.85±5.78),and(94.58±2.14),which were higher than those in the control group(84.15±6.85),(86.63±6.89),(82.55±6.43),and(87.51±6.85),with a statistically significant difference(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Sleeping No.1 capsule combined with Shugan Jieyu capsule can improve the therapeutic effect of insomnia with liver depression and spleen deficiency,accelerate the recovery of sleep quality,alleviate psychological disorders,and improve the quality of life of patients,which is safe and reliable.